相关实验视频

Updated: Jun 4, 2025

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

肢体缺血患者的心脏衰竭和静脉缩功能障碍的主要截肢后的心血管预后

Takuma Takada¹, Eiji Shibahashi², Shun Hasegawa²

¹Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan; Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, Tokyo, Japan.

The American journal of cardiology

|January 2, 2025

概括

患有慢性肢体威胁性缺血症 (CLTI) 和心力衰竭减少排气率 (HFrEF) 的患者的重大截肢 (MA) 可能通过降低血管抵抗来改善心血管结果. 这项研究表明,MA可能是高风险患者的策略.

科学领域:

心脏病学心脏病学
血管外科血管外科
心脏衰竭管理的管理

背景情况:

慢性肢体威胁性缺血 (CLTI) 是一种严重的外周动脉疾病并发症,通常导致截肢.
降低射出分数 (HFrEF) 的心力衰竭显著增加了CLTI患者的死亡风险,部分原因是外周血管阻力升高.
需要进一步研究CLTI,HFrEF和心血管预后之间的相互作用.

研究的目的:

为了评估大截肢 (MA) 对心血管 (CV) 预后在HFrEF的CLTI患者的影响.
为了确定MA是否通过潜在地降低外周血管阻力,在这个高风险人群中影响心血管结果.
为了比较CLTI患者的CV事件HFrEF接受了MA与那些没有经过内血管治疗 (EVT) 后.

主要方法:

对60名CLTI患者进行了回顾性,单中心的观察性研究,这些患者患有HFrEF (射出分数<50%),接受了EVT.
在接受MA (n=17) 和未接受MA (n=43) 的患者之间,CV结局的比较.
主要终点:通过卡普兰-梅尔分析和考克斯回归来评估心血管死亡或心力衰竭住院的复合结果.

主要成果:

在MA组中观察到复合CV终点的发生率明显较低 (日志排名测试:p=0.035).
调整后的分析表明,MA与改善心血管预后有显著的关联 (危险比:0.19;95% CI:0.04-0.87).
在MA组中发现总体死亡率下降的趋势,感染是两组的主要死亡原因.

结论:

在患有HFrEF的CLTI患者中,重大截肢可能与心血管事件的减少有关.
在这种高风险患者群体中,MA可能是改善心血管结果的最终策略.
需要进一步的前性研究来证实这些发现.

关键词:

慢性四肢威胁性缺血症是什么血管内治疗疗法血管内治疗心脏衰竭是因为心脏衰竭.这是一个严重的截肢.系统性功能障碍系统性功能障碍

更多相关视频

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

相关概念视频

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Imbalances in Cardiac Output

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...